Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews · Neuromuscular

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 3 · 42.9%Low 4 · 57.1%Moderate 0 · 0%High 0 · 0%

Eculizumab vs placebo

Improvement in disability grade after 4 weeks · adults with severe Guillain‐Barré syndrome (GBS disability score > 2), within 2 weeks form onset

1 finding from 1 review

Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 40 participants
Very low

Eculizumab vs placebo

Improvement in disability grade Defined as achievement of a specified degree of improvement · adults with severe Guillain‐Barré syndrome (GBS disability score > 2), within 2 weeks form onset

Eculizumab showed no clear difference in improvement in disability grade Defined as achievement of a… compared with placebo (low certainty).

1 finding from 1 review

Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes only
RR 0.85 [0.43, 1.69]
2 studies · 40 participants
Low

Eculizumab vs placebo

Time from randomisation until recovery of unaided walking · adults with severe Guillain‐Barré syndrome (GBS disability score > 2), within 2 weeks form onset

1 finding from 1 review

Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 7 participants
Low

Eculizumab vs placebo

Time from randomisation until discontinuation of ventilation (for those ventilated) · adults with severe Guillain‐Barré syndrome (GBS disability score > 2), within 2 weeks form onset

1 finding from 1 review

Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 8 participants
Very low

Eculizumab vs placebo

Death · adults with severe Guillain‐Barré syndrome (GBS disability score > 2), within 2 weeks form onset

Eculizumab showed no clear difference in death compared with placebo (low certainty).

1 finding from 1 review

Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes only
RR 1.5 [0.08, 26.86]
2 studies · 38 participants
Low

Death or disability after 12 months In the absence of data at 12 months, we report the outcome at 6 months · adults with severe Guillain‐Barré syndrome (GBS disability score > 2), within 2 weeks form onset

It is very uncertain whether eculizumab changes death or disability after 12 months In the absence of data at 12… compared with placebo (very low certainty).

1 finding from 1 review

Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes only
RR 1.21 [0.15, 10.11]
2 studies · 38 participants
Very low

Eculizumab vs placebo

Participants with 1 or more serious adverse events · adults with severe Guillain‐Barré syndrome (GBS disability score > 2), within 2 weeks form onset

Eculizumab showed no clear difference in participants with 1 or more serious adverse events compared with placebo (low certainty).

1 finding from 1 review

Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes only
RR 1.9 [0.34, 10.5]
2 studies · 41 participants
Low